Gokmen, Selma SuerKazezoglu, CemalTabakoglu, ErhanGungor, OzgulAltiay, GundenizTure, Mevlut2024-06-122024-06-1220100250-4685https://hdl.handle.net/20.500.14551/24352Objectives: To investigate the effect of cisplatin+etoposide therapy on serum total and lipid-bound sialic acid levels in patients with non-small cell lung cancer and evaluate the role of these parameters in the monitoring of the therapy. Patients and Methods: To 18 patients (all men) who are newly diagnosed as nonsmall cell lung cancer, cisplatin was given intravenously (80mg/m(2)) on day 1 and etoposide was given (100mg/m(2)) on day 1-3 to the patients once at an interval of 21 day. Blood samples before the first chemotherapy were compared with those obtained after the second and third chemotherapy. The percent of chemotherapy responses of patients were also calculated. Total and lipid-bound sialic levels were determined by the methods of Warren and Katopodis, respectively. Results: There was a significant decrease in serum lipid-bound sialic acid levels after the second chemotherapy when compared with those before the first chemotherapy (t=2.216, p=0.041). Positive response to cisplatin+etoposide therapy was observed in 88.89% (11.11% of total response, 44.44% of partial response and 33.33% of stable response) of the patients. Progressive disease was established in only 11.11% of the patients. It was found a statistically significant decrease in both serum total (t=2.924, p=0.017) and lipid-bound sialic acid (t=3.635, p=0.005) levels after the third chemotherapy when compared with those before the first chemotherapy. Conclusion: Determination of serum total and lipid-bound sialic acid levels besides routine applications may be useful in the monitoring of cisplatin+etoposide therapy.trinfo:eu-repo/semantics/closedAccessTotal Sialic AcidLipid-Bound Sialic AcidNon-Small Cell Lung CancerCisplatin Plus Etoposide TherapyB16f-10 Melanoma-CellsAntimetastatic ActivityMetastasisInhibitionTumorMiceCarcinogenesisExpressionCarcinomaSurfaceArticle353236242Q4WOS:000282700000012